Drugs / RPH-030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07543744 | Apr 2025 → May 2026 overdue | colorectal cancer | R-Pharm | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPH-030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07543744 ↗ |
| Route | Intravenous | “6 mg/kg intravenously (IV)” NCT07543744 ↗ |